Centene (CNC) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2025, Centene (CNC) reported revenue of $49.69 billion, up 18.2% over the same period last year. EPS came in at $0.50, compared to $1.62 in the year-ago quarter.The reported revenue represents a surprise of +4.35% over the Zacks Consensus Estimate of $47.62 billion. With the consensus EPS estimate being -$0.21, the EPS surprise was +338.1%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Centene performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total Medical Health (Benefits) loss Ratios -Total Ratio (HBR): 92.7% versus 93% estimated by five analysts on average.Membership Medicaid - High Acuity Medicaid: 1.59 million versus 1.6 million estimated by four analysts on average.Membership by line of business - Medicare PDP: 7.97 million compared to the 7.88 million average estimate based on four analysts.Membership by line of business - Medicare: 1.01 million compared to the 1.03 million average estimate based on four analysts.Revenues- Premium: $44.13 billion versus the five-analyst average estimate of $42.81 billion. The reported number represents a year-over-year change of +22.2%.Revenues- Service: $772 million compared to the $727.33 million average estimate based on five analysts. The reported number represents a change of -1.5% year over year.Revenues- Premium and service revenues: $44.9 billion versus the five-analyst average estimate of $43.54 billion. The reported number represents a year-over-year change of +21.7%.Revenues- Premium tax: $4.79 billion versus the five-analyst average estimate of $4.07 billion. The reported number represents a year-over-year change of -6.5%.Revenues- Premium and service revenues- Medicaid: $23.17 billion versus $22.33 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.7% change.Revenues- Premium and service revenues- Commercial: $10.99 billion versus the three-analyst average estimate of $10.41 billion. The reported number represents a year-over-year change of +26.5%.Revenues- Premium and service revenues- Medicare: $9.39 billion compared to the $9.53 billion average estimate based on three analysts. The reported number represents a change of +66.4% year over year.Revenues- Premium and service revenues- Other: $1.34 billion versus $1.25 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change.View all Key Company Metrics for Centene here>>>Shares of Centene have returned -7% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Centene Corporation (CNC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks